Have to agree with you here Hernando. I'm looking forward to seeing some advancement in Iluvien sales with the upcoming Alimera CC in March.
Many of us thought this very thing about Alimera's Iluvien. This was because at the time there were no approved drugs for DME. Then, the anti VEG-F's and Ozurdex got approved long before Iluvien for the indication. So, many have been here for a very long time. And though we recognize the broad potential of the company, just as you do, we've watched timelines extend for years. We'll most likely all be here just the same in spite of the company missing them.
Vero, They've spent money like drunken sailors for the last year. They've had a sales force with retina doc's not wanting to buy the drug and wait months on end to get paid. Hopefully, by the next CC, there will be some sign of increased sales with the J code. If not, raising money in this environment will leave a mark.
Sad to say....besides great data on Medidur, we've got 6-8 months of volatility in a company that announces little news to boost its SP. So, the new Hedge funds that came it at $4 look just as clueless as we do. Don't they? Why on earth buy 4 million shares at $4 when you can watch pSivida stock drop to $3 or less.......three weeks later? Now I know the broad market stinks and bio's in particular are getting slammed. pSivida has always been undervalued but still not immune to a broad sell off. I wish I knew....in the meantime, I scratch my head as to what if anything is happening behind the scenes. Most Hedge funds aren't as dumb as we are, so why buy in when they did? Now that I've had time to reflect on the sequence of events, this wasn't Paul's finest moment with selling stock, raising capital below his sale price, then watching the SP free fall immediately thereafter. If I saw it coming, I would have sold all my position at the highs, only to buy it back at current levels. After all , 45% is a lot of capital.
I do not recall that.......but it's a rough patch we're all going through, to say the least........
Wow, what an interesting couple of weeks. Didn't see it playing out this way, but that's why I don't run a public biotech company. Do I wish the capital raise were more than $4....oh yeah. Will there be more clarity when the form 13's come out, hope so; lot's of shares got traded. Hopefully, there will be some general company updates we can hang our hat on. It's been a rough ride for me.....though I'm still way long. Just wish it were summer.........for many reasons.
Kool. 52 week high and low in 30 trading days. The $4/share capital raise, though helpful to the company coffers, continues to be painful for all shareholders. Mid February will show the form 13's for positions prior to the end of the year, they might be interesting as the volume clearly allowed for movement.
Great thread guys. A bit of pain all over the market to say the least. But you know the phone is ringing at management headquarters. Paul let the world know that a partner in the EU would be well received. It does make the Durasert platform look particularly attractive when two "back of the eye diseases'' are managed very well for three years through sustained release and a nickel worth of steroid. Wet and dry AMD are next with repurposed drugs.
I'll try to sleep on those thoughts tonight Frank. It's a company specific market. I think we picked a good one here, but it still may not have total clarity for some time. GL.
Ozurdex is inserted with a 22 gauge needle. Iluvien is 25 and Medidur will be a 27 gauge. Pull up images on the web, big differences.
I'd love to see pSivida's EU partner.....and we don't know who that'll be, step up and take on the Iluvien product. It will have a niche fit in DME but it might take a big pharma name to sell it. With Ozurdex on the market and filling the short term steroid niche, it's only a matter of time before clients want a more long term
option. You can't blame a patient for not wanting to go get a shot in the eye every four months with a 22 gauge needle. One every three years sounds more tolerable.
So, is it a buy at $3.96? We know it's a sell at $5.35. Does the broad market sentiment keep the price dropping until HSS news, EU update or partner on Uveitis? Do like the volume, but the new owners on news of PIII data might be behind in the trade, unless Paul has something up his sleeve. Interesting as always.
I'm having a cocktail overlooking my half mile of pure wild trout water in Colorado. I'm a long here and you're a dooshbag ..waiting for tomorrows headlines that may not materialize. You'll be long gone by the time I reap my profits from this company. Paul Ashton is building this company and I trust him; you don't. If you can't handle the price movement of small companies in the capital markets, get the **&^ out of it. But, do us all a favor and just go away. I'm in the green because I've owned this company a long time and I do my best at understanding the fundamentals. You will forever be a dooshbag and bit&^%er . I'm going to forever call you out on your BS.
I agree Nord. If it were profit taking, don't you think they'd taken them in the high 4's? Yep, they're just trying to scare new holders and it may be working to some extent. Looks like some of our new owners are just like our old owners. The golden cross appears to have given way to a sell off by the shorts when it didn't go higher. Doesn't matter.......when Paul didn't hit the ATM, it just says he's got something up his sleeve.......like more catalysts to move the MC higher. GL.